undamentalytics Newsletter
Sign in

Humacyte, Inc. income statement

In fiscal 2025, Humacyte, Inc. reported revenue of $2.0m, operating income of −$108m (a -5306.0% margin) and net income of −$40.8m, or −$0.26 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue022
Cost of revenue01013
Gross profit0−8−10
Research and development896969
General and administrative2631—
Operating income−114−108−111
Interest expense91110
Income before tax—−41—
Income tax000
Net income−149−41−97
Diluted EPS−$1.26−$0.26−$0.50
Diluted shares (average)118m158m194m
EBITDA−109−103−106

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HUMA vs KRSACLGN vs HUMAHUMA vs KRRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Humacyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Humacyte, Inc.